Innovative Nanosuspension Formulation for Targeted Uveitis Therapy

The purpose of this study was to use a polymeric nanoparticulate drug delivery technology to increase the therapeutic effectiveness of triamcinolone acetonide (TA) for the treatment of uveitis. A modified emulsification/solvent diffusion approach was used to manufacture polyethylene glycol 4000(PEG 4000) nanosuspensions while optimizing processing variables influencing drug loading and particle size. In vitro release studies, X-ray powder diffraction, differential scanning calorimetry, and scanning electron microscopy are examples of physicochemical characterisation. Confirmed the formulation's properties. In vitro studies using a 195nm nanosuspension demonstrated significant improvements in TA release compared to conventional formulations. Therapeutic efficacy evaluations in various groups further underscored the nanosuspensions superior effectiveness in treating uveitis. This approach highlights the potential of sustained-release TA nanosuspensions as promising topical treatments, potentially enhancing patient compliance. Additionally, the review discusses incorporating immunosuppressant into ophthalmic nanodrug delivery systems, emphasizing their benefits in improving drug solubility, bioavailability, eye-targeted specificity, and minimizing systemic side effects, thereby advancing ophthalmic therapeutics.